公开(公告)号：US20200325130A1

公开(公告)日：2020-10-15

申请号：US16848290

申请日：2020-04-14

申请人： YALE UNIVERSITY

发明人： Craig CREWS ,  Momar TOURE ,  Eunhwa KO ,  Saul JAIME-FIGUEROA

IPC分类号： C07D417/14 ,  C07K5/06 ,  C07K5/062 ,  A61K47/55 ,  A61K47/54

摘要： The present invention includes novel compounds and methods for preventing or treating diseases associated with and/or caused by overexpression and/or uncontrolled activation of a tyrosine kinase in a subject in need thereof. In certain embodiments, the compounds of the present invention comprise a tyrosine kinase inhibitor, a linker and a ubiquitin ligase binder. The methods of the present invention comprise administering to the subject an pharmaceutically effective amount of at least one compound of the invention.

公开(公告)号：US20180186785A1

公开(公告)日：2018-07-05

申请号：US15909521

申请日：2018-03-01

申请人： YALE UNIVERSITY

发明人： Craig CREWS ,  Momar TOURE ,  Eunhwa KO ,  Saul JAIME-FIGUEROA

IPC分类号： C07D417/14

CPC分类号： C07D417/14 ,  A61K47/55 ,  A61K47/555 ,  C07K5/06 ,  C07K5/06034

摘要： The present invention includes novel compounds and methods for preventing or treating diseases associated with and/or caused by overexpression and/or uncontrolled activation of a tyrosine kinase in a subject in need thereof. In certain embodiments, the compounds of the present invention comprise a tyrosine kinase inhibitor, a linker and a ubiquitin ligase binder. The methods of the present invention comprise administering to the subject an pharmaceutically effective amount of at least one compound of the invention.

公开(公告)号：US20170121321A1

公开(公告)日：2017-05-04

申请号：US15341275

申请日：2016-11-02

申请人： YALE UNIVERSITY

发明人： Craig CREWS ,  Momar TOURE ,  Eunhwa KO ,  Saul Jaime-Figueroa

IPC分类号： C07D417/14

CPC分类号： C07D417/14 ,  A61K47/55 ,  A61K47/555 ,  C07K5/06 ,  C07K5/06034

摘要： The present invention includes novel compounds and methods for preventing or treating diseases associated with and/or caused by overexpression and/or uncontrolled activation of a tyrosine kinase in a subject in need thereof. In certain embodiments, the compounds of the present invention comprise a tyrosine kinase inhibitor, a linker and a ubiquitin ligase binder. The methods of the present invention comprise administering to the subject an pharmaceutically effective amount of at least one compound of the invention.